Abstract
Background: Insulin has been included in a variety of dosage forms; nevertheless, liposomes have shown protection to degradation and better absorption. The addition of surfactant to liposomes could give the ability to deform and pass through intact membranes, and could increase the stability and the release of the drug.
Introduction: Due to the limitations of the current treatment of insulin in diabetic patients, investigation in alternatives routes has increased. The oral route is the most convenient because of the similarity with the natural secretion of this hormone. The aim was to evaluate the in-vivo effect of fourteen formulations of Insulin-loaded flexible liposomes with different surfactants by oral and subcutaneous routes.
Methods: Fourteen formulations of insulin were obtained with the addition of different surfactants. Size distribution, polydispersion index and Z potential were obtained for all formulations. In-vivo tests were performed in rats induced with experimental diabetes with streptozotocin, and glucose curves were obtained during 480 minutes.
Results: All formulations by the subcutaneous route caused an optimal reduction in glucose levels. However, the addition of Brij L23 produced a better reduction, lasting for 420 minutes. By the oral route, the reduction of glucose did not reach the normal levels, but the addition of Poloxamer 407 and Brij S10 showed the best reduction in the glucose levels by this route.
Conclusion: The addition of surfactants to the lipid structure can modify the release of the insulin by different routes of administration, but this behavior depends on the characteristics of the surfactant, such as the melting phase transition temperature of the lipid bilayer.
Keywords: Tensoactive, insulin, lipid vesicles, diabetes, nanocarrier, liposome.
Graphical Abstract
[1]
Peppas NA, Kavimandan NJ. Nanoscale analysis
of protein and peptide absorption: insulin absorption using complexation
and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci 2006;
29(3-4): 183-97.
[http://dx.doi.org/10.1016/j.ejps.2006.04.014] [PMID: 16777391]
[http://dx.doi.org/10.1016/j.ejps.2006.04.014] [PMID: 16777391]
[2]
Mahato RI, Narang AS, Thoma L, Miller DD.
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev
Ther Drug Carrier Syst 2003; 20(2-3): 153-214.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v20.i23.30] [PMID: 14584523]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v20.i23.30] [PMID: 14584523]
[3]
Yun Y, Cho YW, Park K. Nanoparticles for oral
delivery: targeted nanoparticles with peptidic ligands for oral protein
delivery. Adv Drug Deliv Rev 2013; 65(6): 822-32.
[http://dx.doi.org/10.1016/j.addr.2012.10.007] [PMID: 23123292]
[http://dx.doi.org/10.1016/j.addr.2012.10.007] [PMID: 23123292]
[4]
Cevc G, Gebauer D, Stieber J, Schätzlein A,
Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low
pore penetration resistance and transport therapeutic amounts of insulin
across the intact mammalian skin. Biochim Biophys Acta 1998; 1368(2):
201-15.
[http://dx.doi.org/10.1016/S0005-2736(97)00177-6] [PMID: 9459598]
[http://dx.doi.org/10.1016/S0005-2736(97)00177-6] [PMID: 9459598]
[5]
Malakar J, Sen SO, Nayak AK, Sen KK.
Formulation, optimization and evaluation of transferosomal gel for
transdermal insulin delivery. Saudi Pharm J 2012; 20(4): 355-63.
[http://dx.doi.org/10.1016/j.jsps.2012.02.001] [PMID: 23960810]
[http://dx.doi.org/10.1016/j.jsps.2012.02.001] [PMID: 23960810]
[6]
Fazel M, Daeihameda M, Osoulia M, Almasia A,
Haeria A, Dadashzadeha S. Preparation, In-Vitro Characterization and
Pharmacokinetic Evaluation of Brij Decorated Doxorubicin Liposomes as a
Po-tential Nanocarrier for Cancer Therapy. Iran. J. Pharm. Res, 2018;
17(Special Issue 2): 33-43.
[8]
Cevc G, Schätzlein A, Richardsen H.
Ultradeformable lipid vesicles can penetrate the skin and other
semi-permeable barriers unfragmented. Evidence from double label CLSM
experiments and direct size measurements. Biochim Biophys Acta 2002;
1564(1): 21-30.
[http://dx.doi.org/10.1016/S0005-2736(02)00401-7] [PMID: 12100992]
[http://dx.doi.org/10.1016/S0005-2736(02)00401-7] [PMID: 12100992]
[9]
Mezei M. Liposomes and the skinLiposomes in
drug delivery; Gregoridadis, G; Florence, AT Patel, H, Eds; Harwood
Academic Publishers:. Switzerland 1993; pp. 24-135.
[10]
Cevc G, Blume G. New, highly efficient
formulation of diclofenac for the topical, transdermal administration in
ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta
2001; 1514(2): 191-205.
[http://dx.doi.org/10.1016/S0005-2736(01)00369-8] [PMID: 11557020]
[http://dx.doi.org/10.1016/S0005-2736(01)00369-8] [PMID: 11557020]
[11]
Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet 2003; 42(5): 461-74.
[http://dx.doi.org/10.2165/00003088-200342050-00004] [PMID: 12739984]
[http://dx.doi.org/10.2165/00003088-200342050-00004] [PMID: 12739984]
[12]
Rajan R, Jose S, Mukund VP, Vasudevan DT.
Transferosomes - A vesicular transdermal delivery system for enhanced
drug permeation. J Adv Pharm Technol Res 2011; 2(3): 138-43.
[http://dx.doi.org/10.4103/2231-4040.85524] [PMID: 22171309]
[http://dx.doi.org/10.4103/2231-4040.85524] [PMID: 22171309]
[13]
Arciniegas S. M: Bernad, M.J.; Lopez, R.;
Torres, R.; Caballero, S.C.; Vargas, D. In-vitro and In-vivo Profiles
and Characterization of Insulin Nanocarriers Based in Flexible Liposomes
Designed for Oral Administration. Lett Drug Des Discov 2019; 16(1)
[14]
Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005; 10(4): 711-9.
[PMID: 16341279]
[PMID: 16341279]
[15]
Park SJ, Choi SG, Davaa E, Park JS.
Encapsulation enhancement and stabilization of insulin in cationic
liposomes. Int J Pharm 2011; 415(1-2): 267-72.
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.061] [PMID: 21645598]
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.061] [PMID: 21645598]
[16]
Szkudelski T. The mechanism of alloxan and
streptozotocin action in B cells of the rat pancreas. Physiol Res 2001;
50(6): 537-46.
[PMID: 11829314]
[PMID: 11829314]
[17]
Trinder P. Determination of glucose in blood
using glucose oxidase with an alternative oxygen receptor. Ann Clin
Biochem 1969; 6: 24-37.
[http://dx.doi.org/10.1177/000456326900600108]
[http://dx.doi.org/10.1177/000456326900600108]
[18]
Malvern. Technical Notes [Online]. Malvern Instruments Lim-ited. http://www.malvern.com/en/support/resource-center/technical-notes/TN101104IntensityVolumeNumber.aspx
[19]
Wriedt, T. Mie Theory, A review. InThe Mie
Theory. Basics and applications. Germany, Springer Series in Optical
Science; Hergert, W.; Wriedt, T., Eds.; 2012, 169, pp. 53-79. In:
[20]
Badran M. Formulation and in vitro evaluation
of flufenamic acid loaded deformable liposome for improved skin
delivery. Dig J Nanomater Biostruct 2014; 9: 83-91.
[21]
Chen M, Liu X, Fahr A. Skin penetration and
deposition of carboxyfluorescein and temoporfin from different lipid
vesicular systems: In vitro study with finite and infinite dosage
application. Int J Pharm 2011; 408(1-2): 223-34.
[http://dx.doi.org/10.1016/j.ijpharm.2011.02.006] [PMID: 21316430]
[http://dx.doi.org/10.1016/j.ijpharm.2011.02.006] [PMID: 21316430]
[22]
Putri DC, Dwiastuti R, Marchaban M, Nugroho
AK. Optimization of mixing temperature and sonication duration in
liposome preparation. J Pharm Sci Commun 2017; 14: 79-85.
[http://dx.doi.org/10.24071/jpsc.142728]
[http://dx.doi.org/10.24071/jpsc.142728]
[23]
Patel HM, Ryman BE. Oral administration of insulin by encapsulation within liposomes. FEBS Lett 1976; 62(1): 60-3.
[http://dx.doi.org/10.1016/0014-5793(76)80016-6] [PMID: 129340]
[http://dx.doi.org/10.1016/0014-5793(76)80016-6] [PMID: 129340]
[24]
Spangler RS. Insulin administration via liposomes. Diabetes Care 1990; 13(9): 911-22.
[http://dx.doi.org/10.2337/diacare.13.9.911] [PMID: 2226109]
[http://dx.doi.org/10.2337/diacare.13.9.911] [PMID: 2226109]
[25]
Choudhari KB, Labhasetwar V, Dorle AK.
Liposomes as a carrier for oral administration of insulin: effect of
formulation factors. J Microencapsul 1994; 11(3): 319-25.
[http://dx.doi.org/10.3109/02652049409040461] [PMID: 8064555]
[http://dx.doi.org/10.3109/02652049409040461] [PMID: 8064555]
[26]
Mustata G, Dinh SM. Approaches to oral drug
delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst
2006; 23(2): 111-35.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v23.i2.20] [PMID: 16952274]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v23.i2.20] [PMID: 16952274]
[27]
Bendayan M, Ziv E, Gingras D, Ben-Sasson R,
Bar-On H, Kidron M. Biochemical and morpho-cytochemical evidence for the
intestinal absorption of insulin in control and diabetic rats.
Comparison between the effectiveness of duodenal and colon mucosa.
Diabetologia 1994; 37(2): 119-26.
[http://dx.doi.org/10.1007/s001250050081] [PMID: 8163044]
[http://dx.doi.org/10.1007/s001250050081] [PMID: 8163044]
[28]
Khan MA, Agarwal V. Composition and method for
preparation of an oral dual con-trolled release formulation of a
protein and inhibitor. US Patent, 2003, 20, 220-254
[29]
TenHoor C, Dressman J. Oral absorption of peptides and proteins. STP Pharma Sci 1992; 2: 301-12.
[30]
Patel HM, Stevenson RW, Parsons JA, Ryman BE.
Use of liposomes to aid intestinal absorption of entrapped insulin in
normal and diabetic dogs. Biochim Biophys Acta 1982; 716(2): 188-93.
[http://dx.doi.org/10.1016/0304-4165(82)90267-7] [PMID: 7046805]
[http://dx.doi.org/10.1016/0304-4165(82)90267-7] [PMID: 7046805]
[31]
Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20(11): 886-98.
[http://dx.doi.org/10.1046/j.1464-5491.2003.01076.x] [PMID: 14632713]
[http://dx.doi.org/10.1046/j.1464-5491.2003.01076.x] [PMID: 14632713]
[32]
Lai SK, Wang YY, Hanes J. Mucus-penetrating
nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug
Deliv Rev 2009; 61(2): 158-71.
[http://dx.doi.org/10.1016/j.addr.2008.11.002] [PMID: 19133304]
[http://dx.doi.org/10.1016/j.addr.2008.11.002] [PMID: 19133304]
[33]
Değim IT, Gümüşel B, Değim Z, Ozçelikay T, Tay
A, Güner S. Oral administration of liposomal insulin. J Nanosci
Nanotechnol 2006; 6(9-10): 2945-9.
[http://dx.doi.org/10.1166/jnn.2006.416] [PMID: 17048502]
[http://dx.doi.org/10.1166/jnn.2006.416] [PMID: 17048502]
[34]
Sipai Altaf Bhai M, Vandana D, Mamatha Y, Prasanth V. Liposomes:An overview. J Pharm Sci Innov 2012; 1(1): 13-21.
[35]
Vijayakumar M, Kosuru R, Vuddanda P, Singh KS,
Singh S. Trans resveratrol loaded DSPE PEG 2000 coated liposomes: An
evidence for prolonged systemic circulation and passive brain targeting.
J Drug Deliv Sci Technol 2016; 33: 125-35.
[http://dx.doi.org/10.1016/j.jddst.2016.02.009]
[http://dx.doi.org/10.1016/j.jddst.2016.02.009]
[37]
Martins S, Sarmento B, Ferreira DC, Souto EB.
Lipid-based colloidal carriers for peptide and protein
delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine
2007; 2(4): 595-607.
[PMID: 18203427]
[PMID: 18203427]
[38]
Zhang P, Huang Y, Makhov AM, Gao X, Zhang P,
Li S. Characterization of spherulites as a lipidic carrier for low and
high molecular weight agents. Pharm Res 2013; 30(6): 1525-35.
[http://dx.doi.org/10.1007/s11095-013-0990-y] [PMID: 23579481]
[http://dx.doi.org/10.1007/s11095-013-0990-y] [PMID: 23579481]
[39]
Kneidl B, Peller M, Winter G, Lindner LH,
Hossann M. Thermosensitive liposomal drug delivery systems: state of the
art review. Int J Nanomedicine 2014; 9: 4387-98.
[PMID: 25258529]
[PMID: 25258529]
[40]
Tagami T, Ernsting MJ, Li SD. Optimization of a
novel and improved thermosensitive liposome formulated with DPPC and a
Brij surfactant using a robust in vitro system. J Control Release 2011;
154(3): 290-7.
[http://dx.doi.org/10.1016/j.jconrel.2011.05.020] [PMID: 21640149]
[http://dx.doi.org/10.1016/j.jconrel.2011.05.020] [PMID: 21640149]
[41]
Thakur R, Das A, Chakraborty A. The fate of
anticancer drug, ellipticine in DPPC and DMPC liposomes upon interaction
with HSA: a photophysical approach. J Photochem Photobiol B 2014;
130(5): 122-31.
[http://dx.doi.org/10.1016/j.jphotobiol.2013.10.016] [PMID: 24322006]
[http://dx.doi.org/10.1016/j.jphotobiol.2013.10.016] [PMID: 24322006]
[42]
Tian JL, Ke X, Chen Z, Wang CJ, Zhang Y, Zhong
TC. Melittin liposomes surface modified with poloxamer 188: in vitro
characterization and in vivo evaluation. Pharmazie 2011; 66(5): 362-7.
[PMID: 21699070]
[PMID: 21699070]
[43]
Grohmann F, Csempesz F, Szogyi M.
Stabilization of small unilamellar DMPC-liposomes by uncharged polymers.
Colloid Polym Sci 1998; 276: 66-71.
[http://dx.doi.org/10.1007/s003960050210]
[http://dx.doi.org/10.1007/s003960050210]
[44]
Zhang W, Wang G, See E, et al. Shaw,
J.P.; Baguley, B.C.; Liu, J.; Amirapu, S.; Wu, Z. Post-insertion of
poloxamer 188 strengthened liposomal membrane and reduced drug irritancy
and in vivo precipitation, superior to PEGylation. J Control Release
2015; 203: 161-9.
[http://dx.doi.org/10.1016/j.jconrel.2015.02.026] [PMID: 25701612]
[http://dx.doi.org/10.1016/j.jconrel.2015.02.026] [PMID: 25701612]
[46]
Mozafari MR, Reed CJ, Rostron C. Cytotoxicity
evaluation of anionic nanoliposomes and nanolipoplexes prepared by the
heating method without employing volatile solvents and detergents.
Pharmazie 2007; 62(3): 205-9.
[PMID: 17416197]
[PMID: 17416197]
Article Metrics
35